Eagle Pharmaceuticals (EGRX)
(Delayed Data from NSDQ)
$3.96 USD
-0.31 (-7.26%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.00 +0.04 (1.01%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
EGRX 3.96 -0.31(-7.26%)
Will EGRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for EGRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EGRX
Down -33.75% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround
Down -26.73% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround
EGRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Canopy Growth Corporation (CGC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Implied Volatility Surging for Eagle Pharmaceuticals (EGRX) Stock Options
4 Undervalued Medical Stocks to Buy Amid High Market Volatility
Other News for EGRX
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
Eagle Pharmaceuticals Struggles with Financial Compliance and Nasdaq Listing
Eagle Pharmaceuticals receives delisting notification from Nasdaq
Eagle Pharmaceuticals announces receipt of delisting notification from Nasdaq